In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1290-1297

  Lischka, Peter ^a   Hewlett, Guy ^a,b   Wunberg, Tobias ^a,c   Baumeister, Judith ^a,d   Paulsen, Daniela ^a   Goldner, Thomas ^a   Ruebsamen Schaeff, Helga ^a   Zimmermann, Holger ^a  

^a AiCuris GmbH   (Germany)

^b HBSC   (Germany)

^c BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^d ABLYNX NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AIC 246; ANTIVIRUS AGENT; DNA; GANCICLOVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; ASSAY; CELL CULTURE; CELL TYPE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFICACY; DRUG INHIBITION; EMBRYO; ENGINEERING; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; IN VIVO STUDY; LABORATORY; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS STRAIN; XENOGRAFT;

ACETIC ACID; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOPATHOGENIC EFFECT, VIRAL; DERMIS; DISEASE MODELS, ANIMAL; FIBROBLASTS; HUMANS; LUNG; MICE; MICE, SCID; QUINAZOLINES; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 77149133052     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01596-09     Document Type: Article

References (36)

1. Adler, S. P., G. Nigro, and L. Pereira. 2007. Recent advances in the prevention and treatment of congenital cytomegalovirus infections. Semin. Perinatol. 31:10-18.
2. Andrei, G., E. De Clercq, and R. Snoeck. 2008. Novel inhibitors of human CMV. Curr. Opin. Investig. Drugs 9:132-145.
3. Andrei, G., E. De Clercq, and R. Snoeck. 2009. Drug targets in cytomegalovirus infection. Infect. Disord. Drug Targets 9:201-222.
4. Andreoni, M., M. Faircloth, L. Vugler, and W. J. Britt. 1989. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J. Virol. Methods 23:157-167.
5. Biron, K. K. 2006. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 71:154-163.
6. Biron, K. K., R. J. Harvey, S. C. Chamberlain, S. S. Good, A. A. Smith III, M. G. Davis, C. L. Talarico, W. H. Miller, R. Ferris, R. E. Dornsife, S. C. Stanat, J. C. Drach, L. B. Townsend, and G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:2365-2372.
7. Biron, K. K., S. C. Stanat, J. B. Sorrell, J. A. Fyfe, P. M. Keller, C. U. Lambe, and D. J. Nelson. 1985. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. U. S. A. 82:2473-2477.
8. Bogner, E. 2002. Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev. Med. Virol. 12:115-127.
9. Boppana, S. B., K. B. Fowler, R. F. Pass, L. B. Rivera, R. D. Bradford, F. D. Lakeman, and W. J. Britt. 2005. Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. J. Pediatr. 146: 817-823.
10. Borst, E. M., K. Wagner, A. Binz, B. Sodeik, and M. Messerle. 2008. The essential human cytomegalovirus gene UL52 is required for cleavage-packaging of the viral genome. J. Virol. 82:2065-2078.
11. Bravo, F. J., R. D. Cardin, and D. I. Bernstein. 2007. A model of human cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 76:104-110.
12. Britt, W. 2008. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr. Top. Microbiol. Immunol. 325:417-470.
13. Buerger, I., J. Reefschlaeger, W. Bender, P. Eckenberg, A. Popp, O. Weber, S. Graeper, H. D. Klenk, H. Ruebsamen-Waigmann, and S. Hallenberger. 2001. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 75:9077-9086.
14. Chong, K. T., S. Modiratt, P. Pagano, and R. Hinshaw. 1999. A novel gelfoam mouse model for human cytomegalovirus (HCMV) replication, abstr. 1956, p. 411. Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC), San Francisco, CA. American Society for Microbiology, Washington, DC.
15. Chou, S. 2008. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 18:233-246.
16. Chou, S., L. C. Van Wechel, and G. I. Marousek. 2006. Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Antimicrob. Agents Chemother. 50:2557-2559.
17. Dollard, S. C., S. D. Grosse, and D. S. Ross. 2007. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev. Med. Virol. 17:355-363.
18. Gilbert, C., and G. Boivin. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49:873-883.
19. Krosky, P. M., M. R. Underwood, S. R. Turk, K. W. Feng, R. K. Jain, R. G. Ptak, A. C. Westerman, K. K. Biron, L. B. Townsend, and J. C. Drach. 1998. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J. Virol. 72:4721-4728.
20. Lischka, P., and H. Zimmermann. 2008. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr. Opin. Pharmacol. 8:541-548.
21. Lorz, K., H. Hofmann, A. Berndt, N. Tavalai, R. Mueller, U. Schlotzer-Schrehardt, and T. Stamminger. 2006. Deletion of open reading frame UL26 from the human cytomegalovirus genome results in reduced viral growth, which involves impaired stability of viral particles. J. Virol. 80:5423-5434.
22. Marschall, M., M. Freitag, S. Weiler, G. Sorg, and T. Stamminger. 2000. Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents. Antimicrob. Agents Chemother. 44:1588-1597.
23. Marschall, M., and T. Stamminger. 2009. Molecular targets for antiviral therapy of cytomegalovirus infections. Future Microbiol. 4:731-742.
24. Mercorelli, B., E. Sinigalia, A. Loregian, and G. Palu. 2008. Human cytomegalovirus DNA replication: antiviral targets and drugs. Rev. Med. Virol. 18:177-210.
25. Mettenleiter, T. C., B. G. Klupp, and H. Granzow. 2009. Herpesvirus assembly: an update. Virus Res. 143:222-234.
26. Mocarski, E. S., T. Shenk, and R. Pass. 2007. Cytomegalovirus, p. 2702-2772. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
27. Naesens, L., C. E. Stephens, G. Andrei, A. Loregian, L. De Bolle, R. Snoeck, J. W. Sowell, and E. De Clercq. 2006. Antiviral properties of new arylsulfone derivatives with activity against human betaherpesviruses. Antiviral Res. 72:60-67.
28. Reefschlaeger, J., W. Bender, S. Hallenberger, O. Weber, P. Eckenberg, S. Goldmann, M. Haerter, I. Buerger, J. Trappe, J. A. Herrington, D. Haebich, and H. Ruebsamen-Waigmann. 2001. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J. Antimicrob. Chemother. 48:757-767.
29. Sampathkumar, P., and C. Paya. 2007. Pathogenesis in transplant recipients, p. 7:1-7:14. In V. C. Emery (ed.), Human cytomegalovirus. International Medical Press, London, United Kingdom.
30. Sinzger, C., J. Knapp, B. Plachter, K. Schmidt, and G. Jahn. 1997. Quantification of replication of clinical cytomegalovirus isolates in cultured endothelial cells and fibroblasts by a focus expansion assay. J. Virol. Methods 63:103-112.
31. Sinzger, C., M. Mangin, C. Weinstock, M. S. Topp, H. Hebart, H. Einsele, and G. Jahn. 2007. Effect of serum and CTL on focal growth of human cytomegalovirus. J. Clin. Virol. 38:112-119.
32. Townsend, L. B., R. V. Devivar, S. R. Turk, M. R. Nassiri, and J. C. Drach. 1995. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles. J. Med. Chem. 38:4098-4105.
33. Underwood, M. R., R. J. Harvey, S. C. Stanat, M. L. Hemphill, T. Miller, J. C. Drach, L. B. Townsend, and K. K. Biron. 1998. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 72:717-725.
34. ViroPharma Inc. 2009. Viropharma announces discontinuation of maribavir phase 3 study in liver transplant patients. Company press release. ViroPharma Inc., Exton, PA.
35. ViroPharma Inc. 2009. Viropharma reports results of phase 3 clinical trial for maribavir in bone marrow transplant patients. Company press release. ViroPharma Inc., Exton, PA.
36. Williams, S. L., C. B. Hartline, N. L. Kushner, E. A. Harden, D. J. Bidanset, J. C. Drach, L. B. Townsend, M. R. Underwood, K. K. Biron, and E. R. Kern. 2003. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 47:2186-2192.